全球**兔單株抗體蛋白生技廠Epitomics(F-宜佰)(4149-TW)，今(6)日宣布以1.7億美元與英國上市公司全球蛋白研究工具領導供應商Abcam plc合并，由于公司已被Abcam合并，因此F-宜佰也將確定不在國內上柜。
EpitomicsF-宜佰表示，公司于100年3月2日簽訂并購合約。以總價美金1.7億元元收購全數已發行股份，扣除原有現金1500萬美元後，凈交易價格為美金1.55億元，價款支付方式將以50%現金及50%換股的方式完成。
EpitomicsF-宜佰成立于2001年，總部設于美國加州，資本額約3.62億元臺幣，主要業務為兔單株抗體試劑及客制化委托服務，其中兔單株抗體營收占比50%，客制化抗體30%，另有15-20%來自技術授權的權利金，目前擁有兔單抗產品超過3千種，包括用于抗PEG、乳腺癌、帕金森氏癥及老年癡呆體外檢測等。目前客戶群中95%全球跨國大廠，除羅氏外，尚有Pfizer、Amgen、P&G、拜耳等，其中已有6個抗體用于新藥研發，其中3個進入人體臨床的時程，只要客戶有進展，就可以收錢且不用承擔任何風險。
LONDON (MarketWatch) -- Abcam PLC , which supplies protein research tools, said Monday it has entered into a definitive agreement to buy Epitomics International Inc, an antibody business headquartered in San Francisco, California, with operations in China, for $170.0 million in cash and shares.
MAIN FACTS:
-At completion Epitomics is expected to have net cash of $15.0 million resulting in net consideration for the acquisition of $155.0 million.
-Acquisition is expected to close one to two months' time.
-New GBP20.0 million revolving credit facility put in place to part fund the acquisition.
-Abcam and Epitomics have agreed to a $10.0 million mutual break fee payable in certain circumstances if acquisition doesn't complete.
-Acquisition is expected to be earnings neutral in the first full year of ownership as Company invests in the business to expand production and accelerate growth.
-Acquisition is expected to be earnings enhancing in the second full year of ownership.
-In the year ended Dec. 31, 2011 Epitomics had unaudited revenue of $24.7 million, EBITDA of $7.6 million and profit before tax of $6.8 million; at Dec. 31 Epitomics had net assets of $30.0 million.
-Shares at 0905 GMT up 7 pence, or 2%, at 339 pence valuing the company at GBP609.85 million.